Loading
Befotertinib is an oral kinase inhibitor from Betta Pharmaceuticals Co., Ltd., in registered phase 2 trials for non-small-cell lung cancer.
Befotertinib is listed on ClinicalTrials.gov as an intervention in 1 registered phase 2 trial sponsored by Betta Pharmaceuticals Co., Ltd., in non-small-cell lung cancer. A kinase inhibitor: the name stem -tinib marks a small molecule that blocks a tyrosine kinase driving tumour growth. The registry record does not state which kinase unless named in the trial entries below. OnCo records the agent from the registry alone; approvals, results and the sponsor's own description will follow as they are published.
A kinase inhibitor: the name stem -tinib marks a small molecule that blocks a tyrosine kinase driving tumour growth. The registry record does not state which kinase unless named in the trial entries below.
1.Befotertinib slips into a pocket on its target.
Compare all products across the US, EU, UK, Japan, China and Australia →
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Query for this drug: (TITLE:"Befotertinib" OR ABSTRACT:"Befotertinib") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about Befotertinib, not a curated reading list.
Shares Non-small-cell lung cancer and the tags pipeline, registry-only.
Shares Non-small-cell lung cancer and the tags pipeline, registry-only.
Shares Non-small-cell lung cancer and the tags pipeline, registry-only.
Shares Non-small-cell lung cancer and the tags pipeline, registry-only.
Shares Non-small-cell lung cancer and the tags pipeline, registry-only.
Shares Non-small-cell lung cancer and the tags pipeline, registry-only.
Shares Non-small-cell lung cancer and the tags pipeline, registry-only.
Shares Non-small-cell lung cancer and the tags pipeline, registry-only.